Furthermore, a previous study showed that the 3‐year OS after allo‐HCT was similar between patients with AML including intermediate cytogenetic risk and AML with BCR::ABL1 fusion (62.7%; 95% CI: 61.0%–64.3% and 73.3%; 95% CI: 51.5%–86.4%, p = 0.42); however, it differed significantly between patients with AML including poor cytogenetic risk and AML with BCR::ABL1 fusion (49.7%; 95% CI: 45.9%–53.4% and 73.3%; 95% CI: 51.5%–86.4%, p = 0.049) [10]. This evidence concerns the gene BCR and acute myeloid leukemia.